Phosphodiesterase Inhibitors

K.M. Ferguson and K. Loughney, Identification and Quantification of PDE Isoenzymes and Subtypes by Molecular Biological Methods.

H. Tenor and C. Schudt, Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods.

K.F. Rabe, Effects of Theophylline and Nonselective Xanthine Derivatives on PDE Isoenzymes and Cellular Function.

R.K. Sharma, Interaction of PDE I Inhibitors with Isoenzymes and Cell Functions.

R. Fischmeister, EHNA as an Inhibitor of PDE II.

V.C. Manganiello, PDE II Inhibitors as Therapeutic Agents.

M.A. Giembycz, Interaction of PDE IV Inhibitors with Enzymes and Cell Functions and their Therapeutic Potential.

P.J. Silver, Inhibition of PDE Isoenzymes and Cell Function by Selective PDE V Inhibitors.

J.D. Corbin, Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE V and PDE I.

A. Hatzelmann, Enzymatic and Functional Inhibition of Dual-Selective Inhibitors.

R. Alvarez, Subtype Selectivity, Inhibition of Cell Function and Therapeutic Potential of RS 25344.

J.E. Souness, Characterization of Different States of PDE IV by Rolipram and RP 73401.

T.J. Torphy, Functional Significance of Two Sites for Inhibitors at PDE IV. Subject Index.

Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors. Currently a variety of these new inhibitors are under test as potential anti-inflammatory drugs. During the past five years, molecular biology has revealed a superfamily of these phosphodiesterase isoenzymes. This book summarizes the present state of knowledge, as well as giving a comprehensive description of the compounds available. It will be invaluable for everyone who wants to choose the most suitable PDE inhibitor for their research or who is dealing with such drugs in a clinical setting.

• Utilizes actual testing and research of new PDE inhibitors
• Valuable for researchers and students alike

Research level pharmacologists, immunologists, and cell biologists; as a reference text in this area for those involved in degree-level teaching. Pharmaceutical companies.